Archive - March 2018
GSK’s Nucala improves control of severe asthma
Shire’s constipation drug under US review
Novartis’ Xolair® recommended in new global chronic urticaria guideline
Schmidt: Technology progress depends on machine learning
PTC Therapeutics Receives Formal Dispute Resolution Request Decision from the FDA’s Office of New Drugs
Acorda Announces FDA Acceptance of New Drug Application for Inbrija (levodopa inhalation powder)
FDA Accepts Shire’s Biologics License Application (BLA) and Grants Priority Review for Lanadelumab for the Prevention of Attacks in Hereditary Angioedema (HAE) Patients
Allergan Announces FDA Has Extended The Ulipristal Acetate NDA Review Period To August 2018